$8.540
-0.010 (-0.12%)收盤時
CMRX 資訊
CMRX 事件
Chimerix reports Q4 EPS (25c), consensus (28c)
Reports Q4 revenue $57,000, consensus $310,600. "The recent FDA acceptance of the dordaviprone NDA marks an important milestone for Chimerix and offers renewed hope for patients diagnosed with this life-threatening cancer," said Mike Andriole, Chief Executive Officer of Chimerix. "Our mission to bring dordaviprone to patients globally is greatly enhanced by the pending acquisition of Chimerix by Jazz. We continue to prepare to bring dordaviprone to patients in need as quickly as possible."
Chimerix downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Chimerix (CMRX) to Neutral from Buy after the company agreed to be acquired for $8.55 per share in cash by Jazz Pharmaceuticals (JAZZ). The total consideration of approximately $935M reflects about a 72% premium to the closing price on March 4, the analyst noted.
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash
Jazz Pharmaceuticals (JAZZ) and Chimerix (CMRX) announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935M. The transaction has been approved by both companies and is expected to close in the second quarter of 2025. Chimerix's lead clinical asset is dordaviprone, a novel first-in-class small molecule treatment in development for H3 K27M-mutant diffuse glioma, a rare, high-grade brain tumor that most commonly affects children and young adults. There are no U.S. Food and Drug Administration-approved therapies specifically for H3 K27M-mutant diffuse glioma patients; radiation is the most common treatment approach. A New Drug Application for accelerated approval of dordaviprone in recurrent H3 K27M-mutant diffuse glioma was recently accepted and granted Priority Review by FDA. FDA has set a target Prescription Drug User Fee Act action date of August 18, 2025. If approved in the U.S., dordaviprone may be eligible for a Rare Pediatric Disease Priority Review Voucher. Separately, dordaviprone is being studied in the ongoing Phase 3 ACTION trial, evaluating its use in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation treatment, potentially extending this treatment option into the front-line setting. Under the terms of the merger agreement, Jazz will commence an all-cash tender offer to acquire all outstanding shares of Chimerix's common stock, whereby Chimerix shareholders will be offered $8.55 per share in cash, representing a total consideration of approximately $935 million. This reflects an approximately 72% premium based on the closing trading price on March 4, 2025. Upon the successful completion of the tender offer, Jazz will acquire all shares not acquired in the tender through a second-step merger for the same consideration per share paid in the tender offer.Jazz expects to fund the transaction through existing cash and investments. The transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Chimerix's voting common stock and other conditions. Chimerix's Board of Directors unanimously recommends that Chimerix shareholders tender their shares in the tender offer.
Jazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cash, or $935M
Jazz Pharmaceuticals (JAZZ) and Chimerix (CMRX) announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935M. The transaction has been approved by both companies and is expected to close in the second quarter of 2025. Upon the successful completion of the tender offer, Jazz will acquire all shares not acquired in the tender through a second-step merger for the same consideration per share paid in the tender offer. Jazz expects to fund the transaction through existing cash and investments. The transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Chimerix's voting common stock and other conditions. Chimerix's Board of Directors unanimously recommends that Chimerix shareholders tender their shares in the tender offer.
Chimerix submits dordaviprone NDA for accelerated approval
Chimerix confirms that the Company has submitted a New Drug Application with the U.S. Food and Drug Administration seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma in the United States. Chimerix has requested Priority Review for the NDA. If granted, the resulting six-month FDA review period is expected to result in a potential Prescription Drug User Fee Act action date in the third quarter of 2025. Dordaviprone has received Rare Pediatric Disease Designation for H3 K27M-mutant glioma and has applied for a Rare Pediatric Disease PRV as part of this NDA submission. In addition, the Company announced it entered into an amended and restated loan and security agreement for up to $30 million with Silicon Valley Bank, a division of First-Citizens Bank. Under the terms of the agreement, Chimerix may draw down up to $20.0 million through the period ending February 28, 2026. An additional $10 million may also be made available upon the Company's request through February 28, 2027, subject to SVB's approval. No draws have been made on this facility to date.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。